Диссертация (1141189), страница 24
Текст из файла (страница 24)
– P. 1445 - 1454.93.!Mehran, R. Cessation of dual antiplatelet treatment and cardiac events afterpercutaneous coronary intervention (PARIS): 2 year results from a prospectiveobservational study / R. Mehran, U. Baber, P.G. Steg et al. // Lancet. – 2013. –Vol.382, № 9906. – P. 1714 - 1722.94.!Loh, J.P. Impact of early versus late clopidogrel discontinuation on stenthrombosis following percutaneous coronaryintervention with first- and second-152!generation drug-eluting stents / J.P. Loh, R. Torguson, L.K.
Pendyala et al. // AmericanJournal of Cardiology. – 2014. – Vol. 113, № 12. – P. 1968 - 1976.95.!Mauri, L. Twelve or 30 months of dual antiplatelet therapy after drug-elutingstents / L. Mauri, D.J. Kereiakes, R.W. Yeh et al. // New England Journal of Medicine.– 2014. – Vol. 371, № 23. – P. 2155 - 2166.96.!Комаров, А.Л. Частота поражений различных сосудистых бассейнов имедикаментозное лечение больных с высоким риском атеротромботическихосложнений. Российские результаты международного исследования AGATHA /А.Л.
Комаров, Е.П. Панченко // Кардиология. – 2004. – № 44 (11). – C. 39 - 44.97.!Schulz-Schüpke, S. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting / S.Schulz-Schüpke, R.A. Byrne, J.M. Ten Berg et al. // European Heart Journal. – 2015. –Vol. 36, № 20. – P. 1252 - 1263.98.!Navarese, E.P.
Optimal duration of dual antiplatelet therapy after percutaneouscoronary intervention with drug eluting stents: meta-analysis of randomized controlledtrials / E.P. Navarese, F. Andreotti, V. Schulze et al. // British Medical Journal. – 2015.– Vol. 350. – P. 1 - 12.99.!Рабочая группа по лечению стабильной ИБС Европейского обществакардиологов (ESC).
Клиническирекомендации ESC по лечению стабильнойишемической болезни сердца // Российский кардиологический журнал. – 2015. –№ 7 (111). – C. 7 - 79.100.! Montalescot, G. 2013 ESC guidelines on the management of stable coronaryartery disease: the Task Force on the management of stable coronary artery disease ofthe European Society of Cardiology / G. Montalescot, U. Sechtem, S. Achenbach et al.// European Heart Journal. – 2013.
– Vol. 34, № 38. – P. 2949 - 3003.101.!Кухарчук, В.В. Диагностика и лечение хронической ишемическойболезни сердца. Клинические рекомендации [Электронный ресурс] / В.В.Кухарчук,А.А.Лякишев,http://medi.ru/doc/a030923.htmlВ.П.Лупановисоавт.–Режимдоступа:153!102.!Cutlip, D.E. Clinical end points in coronary stent trials: a case for standardizeddefinitions / D.E. Cutlip, S. Windecker, R. Mehran et al.
// Circulation. – 2007. – Vol.115, № 17. – P. 2344 – 2351.103.!Thygesen, K. Third universal definition of myocardial infarction / K.Thygesen, J.S. Alpert, A.S. Jaffe and writing group on behalf of the JointESC/ACCF/AHA/WHF Task Force for the Universal Definition of MyocardialInfarction // Glob Heart. – 2012, – Vol.7, № 4. – P. 275-295.104.! Российские рекомендации. Диагностика и лечение больных острыминфарктоммиокардасподъемомсегментаSTэлектрокардиограммы.[Электонный ресурс] – Режим доступа: http://acutecardio.ru/article/23/diagnostika-ilechenie-bolnyih-ostryim-infarktom-m105.! Furie, K.L.
Guidelines for the prevention of stroke in patients with stroke ortransient ischemic attack: a guideline for healthcare professionals from the americanheart association american stroke association / K.L. Furie, S.E. Kasner., R.J. Adams etal. // Stroke. – 2011. – Vol. 42, № 1. – P. 227 - 276.106.! Konstantinides, S.V. 2014 ESC guidelines on the diagnosis and management ofacute pulmonary embolism / S.V. Konstantinides, A. Torbicki , G Agnelli et al. //European Heart Journal. – 2014. – Vol. 35, № 43. – P. 3033 - 3069.107.! Erbel, R.
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases:Document covering acute and chronic aortic diseases of the thoracic and abdominalaorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseasesof the European Society of Cardiology / R.
Erbel, V Aboyans, C. Boileau et al. //European Heart Journal. – 2014. – Vol. 35, № 41. – P. 2873 - 2926.108.! Кухарчук, В.В. Диагностика и коррекция нарушений липидного обмена сцелью профилактики и лечения атеросклероза. Российские рекомендации (Vпересмотр). / В.В. Кухарчук, Г.А. Коновалов, А.В. Сусеков и комитет эксертовРоссийскогоизучениюкардиологическогоатеросклерозаиобщества,РоссийскогоНациональногообществаобществапокардиосоматическойреабилитации и вторичной профилактики // [Электронный ресурс] – Режимдоступа: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf.154!109.!Cockcroft, D.W.
Prediction of creatinine clearance from serum creatinine /D.W. Cockcroft, M.H. Gault // Nephron. – 1976. - Vol. 16. - P. 31 - 41.110.!Levey, A.S. Using standardized serum creatinine values in the modification ofdiet in renal disease study equation for estimating glomerular filtration rate / A.S.Levey, J. Coresh, T.Greene et al. // Annals of Internal Medicine. – 2006.
- Vol. 145, №4. – P. 247 - 254.111.!Lyon, E. Mutation detection using fluorescent hybridization probes and meltingcurve analysis. Expert / E. Lyon // Rev. Mol. Diagn. – 2001. - Vol. 1, № 1. - P. 92 101.112.!Pont-Kingdon, G. Direct molecular haplotyping by melting curve analysis ofhybridization probes: beta 2-adrenergic receptor haplotypes as an example / G.
PontKingdon., E. Lyon. // Nucleic Acids Research. – 2005. – Vol. 33, № 10. – P. 89.113.! Gibbons, R.J. ACC/AHA. ACC/AHA 2002 guideline update for exercise testing:summary article: a report of the American College of Cardiology/American HeartAssociation Task Force on Practice Guidelines / R.J. Gibbons, G.J. Balady, J.T.Bricker et al.
/ Circulation. – 2002. – Vol. 106, № 14. – P. 1883 - 1892.114.!Judkins, M.P. Selective coronary arteriography: I. A percutaneous transfemoraltechnic / M.P. Judkins // Radiology. – 1967. – Vol. 89, №5. – P. 815 – 824.115.!Amplatz, K. Mechanics of selective coronary artery catheterization via femoralapproach / K. Amplatz, G. Formanek, P. Stranger et al. // Radiology.
– 1967. – Vol. 89,№ 6. – P. 1040 – 1047.116.!Kastrati, A. Prognostic value of the modified American College of Cardiology.American Heart Association stenosis morphology classification for long-termangiographic and clinical outcome after coronary stent placement / A. Kastrati, A.Schomig, S. Elezi et al. // Circulation. – 1999. – Vol.
100, № 12. – P. 1285 - 1290.117.!Haase, J. Experimental validation of geometric and densitometric coronarymeasurements on the new generation Cardiovascular Angiography Analysis System(CAAS II) / J. Haase, J Escaned, E.M. van Swijndregt et al. // Catheterization andCardiovascular Diagnosis. – 1993. – Vol. 30. – P. 104 – 114.155!118.!Roger, V.L. Heart disease and stroke statistics — 2012 update: a report fromthe American Heart Association / V.L. Roger, A.S. Go, D.M. Lloyd-Jones et al. //Circulation.
– 2012. – Vol. 125. – P. e200 - e220.119.!Бокерия,Л.А.Рентгенэндоваскулярнаядиагностикаилечениезаболеваний сердца и сосудов в Российской Федерации / Л.А. Бокерия., Б.Г.Алекян – М.: Издательство НЦ ССХ им. А.Н. Бакулева РАМН, 2011. - 144 с.120.!Steg, P.G. One-year cardiovascular event rates in outpatients withatherothrombosis / P.G. Steg, D.L Bhatt, P.W. Wilson et al.
// JAMA. – 2007. –Vol.297, № 11. – P. 1197 - 1206.121.!Панченко, Е.П. по поручению участников регистра REACH в РФ.Результатытрехлетнегонаблюдениязаамбулаторнымибольнымисклиническими проявлениями атеротромбоза (анализ российской популяциирегистра REACH) / Е.П. Панченко. // Кардиология. – 2009. – №10.
— C. 9 - 15.122.!Wasilewski, J. Who is eligible for randomized trials? A comparison betweenthe exclusion criteria defined by the ISCHEMIA trial and 3102 real-world patientswith stable coronary artery disease undergoing stent implantation in a single cardiologycenter / J. Wasilewski, L. Poloński, A Lekston et al.
// Trials. - 2015. - Vol. 16. - P.411.123.!Lemesle, G. Dual antiplatelet therapy in patients with stable coronary arterydisease in modern practice: prevalence, correlates, and impact on prognosis (from theSuivi d'une cohorte de patients COROnariens stables en region NORd-Pas-de-Calaisstudy) / G. Lemesle, N. Lamblin, T.
Meurice et al. // American Heart Journal. – 2014.– Vol. 168, № 4. – P. 479 - 486.124.! Windecker, S. Revascularisation versus medical treatment in patients with stablecoronary artery disease: network meta-analysis / S. Windecker, S. Stortecky, G.G.Stefanini et al. // British Medical Journal. – 2014. – Vol. 23, № 348. – P.
g3859.125.! Steg, P.G. Bleeding in acute coronary syndromes and percutaneous coronaryinterventions: position paper by the Working Group on Thrombosis of the EuropeanSociety of Cardiology / P.G. Steg, K. Huber, F. Andreotti et al. // European HeartJournal. – 2011. – Vol. 32, № 15. – P. 1854 - 1864.156!126.! Tantry, U.S. Consensus and update on the definition of on-treatment plateletreactivity to adenosine diphosphate associatedwith ischemia and bleeding / U.S.Tantry, L.
Bonello, D. Aradi et al, working Group on On-Treatment Platelet Reactivity// Journal of the American College of Cardiology. – 2013. – Vol. 17, № 62. – P. 2261 2273.127.! Aradi, D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborativeanalysis on the role of platelet reactivity for risk stratification after percutaneouscoronary intervention / D. Aradi, A. Kirtane, L. Bonello et al. // European HeartJournal. - 2015. – Vol. 14, № 36. – P. 1762 - 1771.128.! Мирзаев, К.Б. Генетические основы резистентности к клопидоглелю:современное состояние проблемы / К.Б.
Мирзаев, Д.А. Сычев, Д.А. Андреев. //Российский кардиологический журнал. – 2015. – №10. – C. 92 - 98.129.! Frelinger, A.L. Clopidogrel pharmacokinetics and pharmacodynamics varywidely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1),noncompliance, diet, smoking, co-medications (including proton pump inhibitors), andpre-existent variability in platelet function / A.L. Frelinger, D.L.
Bhatt, R.D. Lee et al.// Journal of the American College of Cardiology. – 2013. – Vol. 26, № 61. – P. 872 879.130.! Price, M.J. Influence of Genetic Polymorphisms on the Effect of High- andStandard-Dose Clopidogrel After Percutaneous Coronary Intervention / M.J. Price,S.S. Murray., D.J. Angiolillo et al. // Journal of the American College of Cardiology. –2012.
– Vol. 59, № 22. – P. 1928-1937.131.! Комаров, А.Л. Факторы, определяющие клиническую эффективностьклопидогрела и прогноз у больных стабильной формой ишемической болезнисердца / А.Л. Комаров, Е.П. Панченко, А.Е. Донников и соав. // Кардиология. 2011. – № 2. – C. 8 - 18.132.! Mao, L. Cytochrome CYP2C19 polymorphism and risk of adverse clinicalevents in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects / L.Mao, C. Jian, L. Changzhi et al. // Archives of Cardiovascular Diseases. – 2013. – Vol.106, № 10. – P.
517 - 527.157!133.! Gilard, M. 6- versus 24-month dual antiplatelet therapy after implantation ofdrug-eluting stents in patients nonresistant to aspirin: the randomized, multicenterITALIC trial / M. Gilard, P. Barragan, A.A Noryani et al. // Journal of the AmericanCollege of Cardiology. – 2015. – Vol.
65, № 8. – P. 777 - 786.134.! Vavalle, J.P. Impact of bleeding complications on outcomes after percutaneouscoronary interventions / J.P. Vavalle, S.V. Rao // Interventional Cardiology. – 2009. –Vol. 1. – P. 51 - 62.135.! Sibbing, D. Impact of proton pump inhibitors on the antiplatelet effects ofclopidogrel / D. Sibbing, T. Morath , J. Stegherr et al. // Journal of Thrombosis andHaemostasis. – 2009. – Vol. 101, № 4. – P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
